1	Neurodivergence as a risk factor for Post-Covid-19 Syndrome
2	
3	Rachael K. Raw (PhD) ^{1*} , Jon Rees (MBBS) ² , Amy Pearson (PhD) ² and David R. Chadwick
4	(PhD) ³
5	¹ School of Medicine and Health, Newcastle University, Newcastle upon Tyne, UK
6	² The School of Psychology, University of Sunderland, UK
7	³ Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, UK
8	
9	* Corresponding author
10	Rachael Kathleen Raw
11	Email: Rachael.raw3@nhs.net
12	Telephone: +447780652723
13	Manuscript type: Article
14	Key Words: SARS-CoV-2; COVID-19; Long-COVID; Post-Covid-10 Syndrome;
15	Chronic Fatigue Syndrome; Autism; Neurodivergence; Neurotypical.
16	Number of Words: 1776
17	Number of references: 19
18	Number of Tables: 2
19	
20	
21	
22	
23	
24	
25	
26	
27	

28 Abstract

29 Neurodivergent (ND) individuals (e.g., Autistic people) are more likely to experience health 30 problems that are characterised by central sensitisation'. Recent research suggests that a 31 so-called 'Long-COVID' syndrome might also be explained by a heightened response to 32 internal physiological stimuli, much like in myalgic encephalomyelitis/chronic fatigue 33 syndrome (ME/CFS). Using a standardised assessment tool, we examined whether traits 34 associated with Autism would predict long-term COVID-19 symptoms in 267 Healthcare 35 Workers (HCW).. Higher autistic traits predicted COVID-19 symptoms that lasting more than 36 12 weeks regardless of formal autism diagnosis. A personality measure also showed that 37 negative affect was associated with experiencing COVID-19 symptoms for 4-12 weeks, 38 though the direction of causality in this case is uncertain. Limitations of the present study are 39 1) the retrospective nature of COVID-19 symptom reporting; 2) likely self-selection bias 40 given the high number of HCWs who reported long-term COVID-19 symptoms; and 3) the gender-bias towards females in our sample. 41

42

44 Introduction

45 Since the onset of the global COVID-19 pandemic in 2020, researchers have sought to 46 understand the long-term consequences of SARS-CoV-2 infection. Guidelines have been 47 published in attempts to define a 'Long-COVID' syndrome, suggesting that the duration of 48 COVID-19 symptoms can be categorised as either acute COVID-19 Symptoms (AC) lasting 49 up to 4wks post-infection; ongoing symptomatic COVID-19 (OSC) with symptoms up to 50 12wks; or post-COVID-19 syndrome (PCS); when symptoms span beyond 12 weeks - more commonly known as Long-COVID^[1]. Long-term symptoms can include physiological 51 52 sequalae, typically shortness of breath (SOB), cough, headache, myalgia/arthralgia, fatigue 53 and/or psychological outcomes such as cognitive impairment, memory loss, anxiety and 54 depression^[2]. Recent studies suggest that some individuals are more prone to developing 55 long-term symptoms of COVID-19, with females, smokers and those with pre-existing comorbidities being the most at-risk^[3-8]. Furthermore, symptoms of Long-COVID have been 56 57 likened to those that characterise myalgic encephalomyelitis/chronic fatigue syndrome 58 (ME/CFS) - a chronic multi-system condition, that has been found to be triggered by 59 infectious diseases such as Influenza and Coronaviruses^[8,9].

60

61 While the mechanisms underlying ME/CFS are not fully understood, a key theory is that of 62 'Central Sensitization'(CS), whereby the nervous system has an amplified response to 63 certain stimuli. For example, a heightened reaction to nociceptive input may lead to hyperalgesia and thus a heightened experience of pain^[10]. This theory has been applied to 64 65 certain groups, where an amplified internal response to external stimuli is commonplace, 66 such as neurodivergent (ND) people (e.g. Autistic people). Accordingly, a recent study found 67 that a large proportion of autistic individuals met the diagnostic criteria for ME/CFS, as well 68 other conditions characterised by CS, including fibromyalgia and irritable bowel syndrome 69 (IBS). Sixty-percent of autistic participants also scored at or above the clinical cut-off on a screening tool for CS^[10]. Considering this evidence, we aimed to examine whether autistic 70

71 individuals, and those with higher self-reported autistic characteristics are also at greater risk 72 of developing long-term symptoms of COVID-19. As some evidence suggests that Type D 73 traits, including negative affect and social inhibition, are more common in those with conditions such as ME/CFS and fibromyalgia,^[11] this measure was included to control for 74 75 these as a possible confounder. In the present study, we therefore surveyed a group of 76 healthcare workers (HCWs) and asked them about their experience of ongoing COVID-19 77 symptoms. Our main aim was to see whether longer-term COVID-19 symptoms were more 78 common in those who scored higher on a measure of autistic characteristics in ND and Type 79 D Personality (TDP).

80

81 Method

82

83 Ethics Statement

84

All participants gave their written informed consent, and Cambridge East Research Ethics Committee approved this study (Ethics Ref: 20/EE/0161), which was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Data was collected between August and November 2022. Authors were blinded to identifiable participant information.

90

91 Participants

In this observational survey-based study, HCWs were recruited from three Northeast England hospitals and formed an opportunistic sample. HCWs were invited via email to complete an online survey, which was advertised to all HCWs using the weekly communications service.

96

97 Materials and Procedure

98 The anonymous survey explored HCWs' experience of COVID-19 symptoms, including 99 nature, severity and duration. Prior COVID-19 history was defined as previous positive self-100 reported polymerase chain reaction (PCR), antibody (AB) and/or lateral flow test (LFT). 101 HCWs indicated which COVID-19 symptoms they experienced from the following list: chest 102 pain; memory/concentration problems; cough; diarrhoea; fatigue; fever/chills; headache; joint 103 pain; loss taste/sell; muscle pain; nausea/vomiting; SOB; sore throat; swollen lymph nodes. 104 Severity was ranked as 'Mild' (no interference with daily activities); 'Moderate' (some 105 interference); 'Severe' (prevented daily activities); 'Very Severe' (required hospital 106 visit/hospitalisation). Symptoms duration was categorised according to previously cited 107 guidelines^[1], as AC, OCS, or PCS. Vaccination history was also recorded. HCWs were 108 invited to self-declare whether they were neurodivergent. Autistic traits were assessed using the Ritvo Autism & Asperger Diagnostic Scale (RAADS-14)^[12]. TDP was explored using the 109 DS14, a psychometric tool that captures negative affectivity and social inhibition^[13]. Effects of 110 111 age and gender were also considered within our analyses.

112

113 Statistical Analysis

114 Statistical analysis was conducted using JASPv0.16.3.0^[14]. Categorical outcomes were 115 examined with chi-square tests and multinomial regression. Continuous outcomes were 116 investigated using ANOVA. An alpha level of .05 indicating significance was used 117 throughout.

118

119 **Results**

Of the 267 respondents (35 M, 226 F, 6 other; mean age 48.3yrs), 153 (57%) reported one episode of COVID-19, 100 (37%) reported two episodes, and 14 (5%) recalled three or more, which had been diagnosed on positive PCR (208, 78%), LFT (158, 41%) or AB test (33, 12%) with 111 positive on both PCR and LFT. 212 (79.5%) received three doses of vaccine, 23 (8.5%) more than three doses, 24 (9%) had two doses, 3 (1%) one dose and 3 (1%) none. Two (1%) declined to give vaccine information. Regarding COIVD-19 symptoms

126 124 (46%) resolved within 4wks (AC), 64 (24%) between 4-12wks (OCS) and 79 (30%) had
127 symptoms >12wks (PCS).

128

Thirty-eight (14%) self-declared being ND (16 autistic; 14 attention deficit hyperactivity disorder; 21 others including dyslexia, dyscalculia, dyspraxia; 12 with multiple conditions), whilst 7 (3%) declined to answer. There was no significant association between either OCS or PCS and self-declared ND status ($X^2(2)=2.59$, p=.27). Based on the RAADS cut-off of 14, 83 (31%) scored above this threshold and there was a significant association of being above threshold with likelihood of experiencing OCS or PCS ($X^2(2)=10.01$, p=.007).

135

136 There was a significant association between number of COVID-19 episodes and symptom 137 duration ($X^{2}(4)=13.57, p=.009$) with 2 episodes being associated with PCS. Increased 138 symptom number during first episode was reporting by people going on to develop either 139 OCS or PSC (7.5(2.9) or 8.3(3.0) vs 5.1(2.9) symptoms; F(2,272)=34.46, p<.001), with the 140 increased occurrence of every symptom being associated with OCS or PCS except fever 141 and sore throat. Those reporting PCS also reported greater severity of symptoms during the first episode compared to those with OCS, or those whose symptoms resolved ($X^{2}(6)=43.90$, 142 143 p<.001). There was no association of reported first episode symptom severity with ND 144 status ($X^{2}(6)=2.58$, p=.86).

145

Examining the subscales of the RAADS, there was no difference between COVID-19 duration groups on mentalising (F(2,259)=2.37, p=.10) or social anxiety (F(2,259)=2.5, p=0.08), but a significant difference in sensory reactivity (F(2,259)=4.85, p=.009), with posthoc testing showing that there was a significant difference between the AC and PCS (1.62 (2.49) vs 3.81 (3.02)). There was no overall difference in DS14 between the COVID-19

151	duration groups ($F(2,259)=2.41$, p=.09). Negative affectivity was significantly higher in those
152	experiencing OCS ($F(2,272)=3.72$, $p=.03$), but not those with PCS. See Table 1 for HCW
153	characteristics.

154 - Insert Table 1 -

155

156 A multinomial logistic model was constructed with three levels of outcome being symptom 157 duration. Age and gender were included in the model at step one, and the two TDP 158 subscales and three RAADs subscales entered at a second step. The second step resulted 159 in a significant improvement in model fit ($X^2(10)=22.75$, p=.012). Only the DS14 subscale for 160 negative affectivity was a significant predictor of OCS versus AC. PCS was significantly 161 predicted by the RAADS sensory reactivity subscale as well as increasing age and being 162 female. Coefficients are given in Table 2. Repeating the analysis with OCS symptoms as the 163 baseline, none of the factors significantly differentiate that from the PCS group.

164

A similar model revealed that after controlling for age, gender, RAADs sensory reactivity and TDP negative reactivity, OCS was significantly predicted by the presence of SOB (O.R. 6.14 [2.64–14.29], p<.001). PCS was predicted by the occurrence of concentration or memory problems (O.R. 5.59 [2.28–13.72], p<.001), during first episode. Fever during the first episode was associated with lower likelihood of OCS (O.R. 0.37 [0.15–0.90], p=.03 or LC O.R. 0.21 [0.08–0.56], p=.002).

171

172 - Insert Table 2 -

173

174 Discussion

175

Conditions characterised by CS, such as ME/CFS, are more common in those with ASD^[11].
PCS, where symptoms of SARS-CoV-2 infection last beyond 12 weeks^[1], has been likened
to ME/CFS^[8,9]. We explored whether neurodivergent HCWs were more likely to experience
prolonged symptoms of COVID-19 and whether TDP traits are a risk factor for PCS.

180

181 In our sample 30% described having COVID-19 symptoms beyond 12wks post-infection. 182 This is alarmingly high, given the extent to which ongoing COVID-19 symptoms can impact 183 daily life. Loss of earnings, dependency on caregivers, and an inability to perform everyday activities are just a few of the consequences of PCS cited in the recent literature^[15]. Some of 184 185 the previously highlighted risk factors for prolonged COVID-19 symptoms were replicated in 186 the present study, with females and older individuals being more at risk of PCS. Having had 187 multiple episodes of COVID-19 was also associated with longer length of symptoms, and 188 increased symptom number in the first episode was associated with OCS/PCS.

Regarding Type D Personality, TDP traits overall were not different across the AC/OCS/PCS groups. Importantly, the confounder of negative affect was only marginally associated with OCS, and not at all with PCS. The direction of causality in this finding must be carefully considered, as it is unclear as to whether the presence of OCS might have led to greater negative affect, or if those with naturally greater negative affectivity were more likely to have had symptoms for longer because they perhaps did not take the actions necessary to accelerate their recovery (e.g., returning to regular activities).

196

Interestingly only 13% of HCW self-declared that they were neurodivergent, whereas 31% of the group scored above threshold on the RAADS. This is consistent with evidence to suggest that people with fewer stereotypical characteristics frequently go un-diagnosed^[16]. Analyses also revealed that PCS was predicted by the 'sensory reactivity' subscale of the RAADS, suggesting that HCWs who scored highly on this element were more likely to have

202 prolonged symptoms. This finding fits with the theory that a CS mechanism may underlie 203 conditions such as ME/CFS^[9].

204

The main limitations of the present study are the likelihood of self-selection bias given that 30% of HWCS had experienced PCS, that we relied on HCWs to recall symptoms of COVID-19 retrospectively, and that the sample was largely comprised of female participants (85%). Nevertheless, our work provides preliminary evidence to support the sensory reactivity element of neurodivergence as a risk factor for developing Long-COVID. This finding has implications for the provision of treatment services in at-risk groups^[16], particularly psychological interventions, which autistic individuals often find difficult to access^[18,19].

212

213 Conclusion

Our key findings are first, more HCWs scored above threshold for neurodivergence than those who self-declared having been diagnosed neurodivergent; second, there was no association between OCS/PCS and HCWs self-declared neurodivergent status; third, TDP did not differ or predict OCS/PCS, but the negative affectivity subscale was a relatively weak predictor of being in the OCS group; and finally, scoring above or below the RAADS threshold was predictive of PCS, with the sensory reactivity subscale (in addition to age and female sex) predicting COVID-19 symptoms lasting >12 weeks.

221

222

223

- 224
- 225

226

227

- 229
- 230
- 231
- 232
- 233
- 234
- _0.

235 <u>Contributors</u>

236 RKR/JR/DRC/AP conceived the study and DRC is chief investigator of the CHOIS study.

237 RKR acted as site principal investigator. RKR/JR/DRC contributed to the study protocol,

design, and data collection. JR did the statistical analysis. RKR/JR/DRC prepared the

239 manuscript. All authors critically reviewed and approved the final version.

240

241 Financial Disclosure

The CHOIS study was supported by the North East and North Cumbria Academic Health Sciences Network (AHSN; fund awarded to co-author DRC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

246

247 Competing Interests

- 248 The authors have declared that no competing interests exist.
- 249

250 Acknowledgements

251 We would like to thank the CHOIS research team, John Rouse and the North East and North

252 Cumbria NIHR for assistance with the survey.

253

254 Data Availability

255 All data will be made available upon request.

257 References

- 2581. National Institute of Clinical Excellence (NICE), the Scottish Intercollegiate259Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP).
- NICE 'long COVID' guideline. 2021. https://www.guidelines.co.uk/infection/nice-long covid-guideline/455728.article (accessed April 11, 2023).
- Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS et al.
 Symptoms, complications and management of long COVID: a review. *J R Soc Med.* 2021;114(9):428-442. https://doi.org/10.1177/01410768211032850.
- Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T et al. Symptoms
 and risk factors for long COVID in non-hospitalized adults. *Nat Med.* 2022;28(8):1706-1714. https://doi.org/10.1038/s41591-022-01909-w.
- Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR. Prior COVID-19 infection is
 associated with increased Adverse Events (AEs) after the first, but not the second,
 dose of the BNT162b2/Pfizer vaccine. *Vaccine*. 2022;40(3):418-423.
 https://doi.org/10.1016/j.vaccine.2021.11.090.
- Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but
 not Long-COVID, is associated with increased adverse events following
 BNT162b2/Pfizer vaccination. *J Infect.* 2021 ;83(3):381-412.
 https://doi.org/10.1016/j.jinf.2021.05.035.
- Raw RK, Rees J, Chadwick DR. Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine. *PLOS Glob Public Health*. 2023;3(2):e0001053.
 https://doi.org/10.1371/journal.pgph.0001053.
- Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk
 factors, and treatments. *Infect Dis (Lond)*. 2021;53(10):737-754.
 https://doi.org/10.1080/23744235.2021.1924397

- 8. Astin R, Banerjee A, Baker MR, Dani M, Ford E et al. Long COVID: mechanisms, risk
- factors and recovery. *Exp Physiol.* 2023;108(1):12-27.
 https://doi.org/10.1113/EP090802.
- 9. Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-
- 287 infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review.
- 288 Ther Adv Infect Dis. 2021;8:20499361211009385.
- 289 https://doi.org/10.1177/20499361211009385.
- 290 10. Grant S, Norton S, Weiland RF, Scheeren AM, Begeer S, Hoekstra RA. Autism and
 291 chronic ill health: an observational study of symptoms and diagnoses of central
 292 sensitivity syndromes in autistic adults. *Mol Autism*. 2022;13(1):7.
 293 https://doi.org/10.1186/s13229-022-00486-6.
- 11. Ablin JN, Zohar AH, Zaraya-Blum R, Buskila D. Distinctive personality profiles of
 fibromyalgia and chronic fatigue syndrome patients. *PeerJ.* 2016;4:e2421.
 https://doi.org/10.7717/peerj.2421.
- 297 12. Eriksson JM, Andersen LM, Bejerot S. RAADS-14 Screen: validity of a screening tool
 298 for autism spectrum disorder in an adult psychiatric population. *Mol Autism*.
 299 2013;4(1):49. https://doi.org/10.1186/2040-2392-4-49.
- 300 13. Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and
 301 Type D personality. *Psychosom Med.* 2005, 67 (1): 89-97.
 302 https://doi.org/10.1097/01.psy.0000149256.81953.49.
- 303 14. JASP Team (2022). JASP (Version 0.16.3) [Computer software].
- 304 15. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, Alwan NA.
 305 Characteristics and impact of Long Covid: Findings from an online survey. *PLoS* 306 *One.* 2022;17(3):e0264331. https://doi.org/10.1371/journal.pone.0264331.
- 307 16. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. *Eur J* 308 *Pharmacol.* 2020;889:173644. https://doi.org/10.1016/j.ejphar.2020.173644.
- 309 17. Morales Hidalgo P, Voltas Moreso N, Canals Sans J. Autism spectrum disorder
 310 prevalence and associated sociodemographic factors in the school population:

- 311EPINEDstudy.Autism.2021;25(7):1999-2011.
- 312 https://doi.org/10.1177/13623613211007717.
- 18. Camm-Crosbie L, Bradley L, Shaw R, Baron-Cohen S, Cassidy S. 'People like me
 don't get support': Autistic adults' experiences of support and treatment for mental
 health difficulties, self-injury and suicidality. *Autism.* 2019;23(6):1431-1441.
 https://doi.org/10.1177/1362361318816053.
- 317 19. Adams, D., Young, K. A Systematic Review of the Perceived Barriers and Facilitators 318 to Accessing Psychological Treatment for Mental Health Problems in Individuals on 319 the Autism Spectrum. Rev J Autism Dev Disord. 2021;8:436-453. 320 https://doi.org/10.1007/s40489-020-00226-7.
- 321

323	List of	Abbreviations
324		
325	•	AB: Antibody
326	•	AC: Acute COVID-19
327	•	CS: Central Sensitisation
328	•	DS14: Type D Personality Scale
329	•	HCWs: Healthcare Workers
330	•	IBS: Irritable Bowel Syndrome
331	•	LFT: Lateral Flow Test
332	•	ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
333	•	ND: Neurodivergent/Neurodivergence
334	•	OSC: Ongoing Symptomatic COVID-19
335	•	PCR: Polymerase Chain Reaction
336	•	PCS: Post-COVID-19 Syndrome
337	•	RAADS: Ritvo Autism & Asperger Diagnostic Scale
338	•	SOB: Shortness of Breath
339	•	TDP: Type D Personality

341 Tables and Table Captions

342

	AC	OCS	PCS
	n= 124	n =64	n =79
Age (years)	47.1 (11.6)	49.2 (10.0)	49.4 (10.8)
Mdn first episode symptoms	5	8	8
RAADS total	8.40 (9.71)	11.77 (9.40)	10.92 (10.0)
RAADS Mentalising	4.33 (5.25)	6.00 (5.36)	4.95 (5.63)
RAADS Social Anxiety	2.45 (3.15)	3.38 (3.27)	3.17 (3.26)
RAADS Sensory Reactivity	1.62 (2.61)	2.39 (2.49)	2.81 (3.02)
DS14 Total	23.34 (11.46)	27.06 (10.33)	25.09 (10.55)
DS14 Negative Affectivity	11.59 (6.94)	14.33 (6.20)	12.54 (6.29)
DS14 Social Inhibition	11.65 (5.84)	12.73 (5.40)	12.54 (5.90)

343

subscale totals for the RAADs and DS14 and median number of symptoms reported during

346 first COVID-19 episode.

³⁴⁴ **Table 1**. Characteristics of the three patient groups showing mean (SD) for age, totals and

	Estimate (S.E.)	Odds Ratio (95% C.I.)	р
OCS v AC		· · · ·	
Intercept	-2.99 (1.03)		
Age	0.03 (0.02)	1.03 (0.99 – 1.06)	.07
Sex	M: -0.37 (1.34)	0.69 (0.05 – 9.63)	.79
	F-M 0.62 (0.51)	1.86 (0.68 - 5.08)	.23
DS14 Negative Affectivity	0.07 (0.03)	1.07 (1.01 – 1.15)	.04
DS14 Social Inhibition	-0.08 (0.05)	0.92 (0.84 – 1.01)	.92
RAADs mentalising	-0.003 (0.05)	1.00 (0.91 – 1.10)	.95
RAADS Social Anxiety	0.13 (0.08)	1.14 (9.98 – 1.33)	.09
RAADS Sensory Reactivity	0.09 (0.08)	1.10 (0.93 – 1.29)	.27
PCS v AC			
Intercept	-3.10 (1.02)		
Age	0.03 (0.02)	1.03 (1.00 – 1.06)	.04
Sex	M: -0.05 (1.31)	0.96 (0.07 – 12.50)	.97
	F-M: 1.13 (0.54)	3.09 (1.07 – 8.88)	.04
DS14 Negative Affectivity	0.01 (0.03)	1.01 (0.95 – 1.08)	.70
DS14 Social Inhibition	-0.04 (0.05)	0.0.96 (0.88 – 1.05)	.40
RAADs mentalising	-0.07 (0.05)	0.93 (0.85 – 1.02)	.12
RAADS Social Anxiety	0.13 (0.08)	1.14 (0.98 – 1.32)	.09
RAADS Sensory reactivity	0.22 (0.08)	1.25 (1.07 – 1.46)	.004

348

349 Table 2. Coefficients from multinomial logistic regression predicting occurrence of OCS or

350 PCS against baseline AC from the three RAADS and two DS14 subscales.